Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in healthy toddlers and children in Chile.
In this open study, 20 toddlers and 80 schoolchildren received an intramuscular dose of Epaxal and a booster dose 12 mo later to assess the efficacy and safety of this aluminium-free, virosomal hepatitis A vaccine. Four weeks after primary vaccination, 94% of toddlers and 99% of schoolchildren had seroconverted, and all toddlers and 94% of schoolchildren remained seroprotected for 12 mo.


CONCLUSIONS
After vaccination with Epaxal and booster, all subjects were seroprotected. Epaxal was very well tolerated by both age groups.
Riedemann
S
S
Institute of Microbiology, Faculty of Sciences, Universidad Austral de Chile, Valdivia, Chile. sriedema@uach.cl
Reinhardt
G
G
Ibarra
H
H
Frösner
G G
GG
D000293:Adolescent; D000914:Antibodies, Viral / Q000032:analysis; D002648:Child; D002677:Chile; D022362:Hepatitis A Vaccines / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D012044:Regression Analysis; D022701:Virosomes
D000914:Antibodies, Viral; D022362:Hepatitis A Vaccines; D022701:Virosomes